Roche builds evidence for Evrysdi’s benefits in younger SMA patientsRoche has highlighted new data with its oral treatment for spinal muscular atrophy (SMA) – Evrysdi – showing Share XRoche builds evidence for Evrysdi’s benefits in younger SMA patientshttps://pharmaphorum.com/news/roche-builds-evidence-for-evrysdis-benefits-younger-sma-patients/
Biogen plans trial of Spinraza in patients not responding to SMA gene therapyBiogen is planning to trial its Spinraza spinal muscular atrophy (SMA) drug in patients who have not responded Share XBiogen plans trial of Spinraza in patients not responding to SMA gene therapyhttps://pharmaphorum.com/news/biogen-trialling-spinraza-in-patients-not-responding-to-novartis-sma-gene-therapy/
FDA cues up May verdict for Roche’s SMA challenger risdiplamThe FDA has started a priority review of Roche’s spinal muscular atrophy (SMA) candidate risdiplam, with a decision Share XFDA cues up May verdict for Roche’s SMA challenger risdiplamhttps://pharmaphorum.com/news/fda-cues-up-may-verdict-for-roches-sma-challenger-risdiplam/
NHS chief hails SMA drug deal – and was that a swipe at Vertex?Children in England with the rare muscle wasting disease spinal muscular atrophy (SMA) will get access to Biogen’s Share XNHS chief hails SMA drug deal – and was that a swipe at Vertex?https://pharmaphorum.com/news/nhs-chief-hails-sma-drug-deal-and-was-that-a-swipe-at-vertex/
PTC shares soar after SMA drug data impresses marketAfter failing three times to bring their Duchenne therapy to the US market, PTC Therapeutics might be on Share XPTC shares soar after SMA drug data impresses markethttps://pharmaphorum.com/news/ptc-therapeutics-posts-solid-sma-data/
Biogen sees Spinraza slow down in Q3, bullish on Alzheimer’s chancesBiogen has given investors a pleasant surprise with better-than-expected profits in Q3, but has puzzled analysts with a Share XBiogen sees Spinraza slow down in Q3, bullish on Alzheimer’s chanceshttps://pharmaphorum.com/news/biogen-sees-spinraza-slow-q3/
